Results 111 to 120 of about 1,885 (156)

Insights into Monkeypox Virus: Host Immunity, Viral Immune Evasion, Recent Advances in Vaccines, Therapeutic Development, and Future Perspectives. [PDF]

Microorganisms
Chen M, Ren W, Wu X, Khan JM, Nazir H, Rehman SU, Ali F, Li J.   +7 more
europepmc   +1 more source

Monkeypox (Mpox), a Resurging Global Public Health Concern: An Updated Outlook Through 2025. [PDF]

Curr Issues Mol Biol
Islam DZ, Tamanna FS, Fuad M, Shanta MSA, Khanom A, Hasan MM, Sujan MSI, Khandker SS, Reza MS, Akter S, Ahmed MF, Azmuda N, Adnan N, Sina AA.   +13 more
europepmc   +1 more source

The Emerging Threat of Monkeypox: An Updated Overview. [PDF]

Viruses
Yahya G, Mohamed NH, Wadan AS, Castro EM, Kamel A, Abdelmoaty AA, Alsadik ME, Martinez-Sobrido L, Mostafa A.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Brincidofovir: A Novel Agent for the Treatment of Smallpox

Annals of Pharmacotherapy, 2023
Objective: This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of brincidofovir, a nucleotide analogue DNA polymerase inhibitor developed for the treatment of smallpox. Data Sources:
Jessica Huston, Stacey Curtis, Eric F. Egelund   +2 more
openaire   +4 more sources

The use of brincidofovir for the treatment of mixed dsDNA viral infection

Journal of Clinical Virology, 2016
Double-stranded DNA (dsDNA) viral infections constitute a major complication following solid organ and stem cell transplantation. Few therapeutic options are currently available for the treatment of such infections in highly immunocompromised hosts. Brincidofovir is an oral investigational drug with broad antiviral activity against dsDNA viruses in ...
Jose F, Camargo, Michele I, Morris, Lilian M, Abbo, Jacques, Simkins, Seyyedeh, Saneeymehri, Maritza C, Alencar, Lazaros J, Lekakis, Krishna V, Komanduri   +7 more
openaire   +4 more sources

Brincidofovir as Salvage Therapy for Adenovirus Disease in Intestinal Transplant Recipients

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
BackgroundAdenoviruses are double‐stranded DNA viruses that typically cause mild self‐limiting respiratory, ocular, and gastrointestinal infections. In immunocompromised patients, especially transplant recipients, the infection can be severe, with dissemination and multiorgan failure. In intestinal transplant recipients, the incidence is as high as 57%.
Nimisha Sulejmani, Shunji Nagai, Mohamed Safwan, Michael D. Rizzari, Mohammad Raoufi, Marwan S. Abouljoud, Mayur Ramesh   +6 more
openaire   +2 more sources

Brincidofovir

Reactions Weekly, 2021
openaire   +2 more sources

Brincidofovir/immunosuppressants

Reactions Weekly, 2022
openaire   +1 more source